Ahammune Biosciences Secures $5M for Vitiligo Trials
Ahammune Biosciences raises $5M led by pi Ventures for Phase II trials, expanding R&D for skin disease treatments.
- Latest
- Trending
Ahammune Biosciences raises $5M led by pi Ventures for Phase II trials, expanding R&D for skin disease treatments.
Microsoft removes 730,000 apps, enhances security with new measures to protect cloud infrastructure from cyber threats.
Aurora high school students gain real-world cybersecurity skills for immediate job placement.
GitLab patches critical flaw enabling unauthorized pipeline job execution. Users urged to update immediately.
JPMorgan hires Garcia-Salas and Redmond to boost mid-cap banking amid rising market activity.
New Fortress Energy authorized to export LNG to non-FTA countries, boosting energy trade and growth in Latin America.
Discover three stocks poised to meet AI's massive energy needs: Kinder Morgan, Pan American Silver, and Cameco Corp.
Halliburton cyberattack underscores growing threat to critical infrastructure. Robust cybersecurity measures are essential to mitigate risks.
Halliburton experiences IT disruption after potential hack, prompting staff to avoid internal networks amid ransomware concerns.
Canadian Solar's Q2 results disappoint with a 12% share drop. Revenue fell short of expectations.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.